DDInter1764 DDInter336
Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296-299 in the protease domain.
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Tenecteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluoxetine
Fluoxetine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Celecoxib
Tenecteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pentosan polysulfate
Pentosan polysulfate {u} (Compound) causes {v} (Side Effect) Constipation
Constipation {u} (Side Effect) is caused by {v} (Compound) Celecoxib
Tenecteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epoprostenol
Epoprostenol {u} (Compound) palliates {v} (Disease) systemic scleroderma
systemic scleroderma {u} (Disease) is palliated by {v} (Compound) Celecoxib
Tenecteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ketorolac
Ketorolac {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Nonsteroidal Anti-inflammatory Compounds {u} (Pharmacologic Class) includes {v} (Compound) Celecoxib
Tenecteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Celecoxib
Tenecteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} (Compound) downregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is upregulated by {v} (Compound) Celecoxib
Tenecteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} (Compound) upregulates {v} (Gene) ZMIZ1
ZMIZ1 {u} (Gene) is downregulated by {v} (Compound) Celecoxib
Tenecteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfinpyrazone
Sulfinpyrazone {u} (Compound) upregulates {v} (Gene) ST3GAL5
ST3GAL5 {u} (Gene) is upregulated by {v} (Compound) Celecoxib
Tenecteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lisinopril
Lisinopril {u} (Compound) treats {v} (Disease) systemic scleroderma
systemic scleroderma {u} (Disease) is palliated by {v} (Compound) Celecoxib
Tenecteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Icosapent
Icosapent {u} (Compound) downregulates {v} (Gene) RBM34
RBM34 {u} (Gene) is downregulated by {v} (Compound) Celecoxib
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and Fluoxetine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Celecoxib (Compound)
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate and Pentosan polysulfate (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Celecoxib (Compound)
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol (Compound) palliates systemic scleroderma (Disease) and systemic scleroderma (Disease) is palliated by Celecoxib (Compound)
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac and Ketorolac (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) and Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) includes Celecoxib (Compound)
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Celecoxib (Compound)
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) downregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Celecoxib (Compound)
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) upregulates ZMIZ1 (Gene) and ZMIZ1 (Gene) is downregulated by Celecoxib (Compound)
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Sulfinpyrazone and Sulfinpyrazone (Compound) upregulates ST3GAL5 (Gene) and ST3GAL5 (Gene) is upregulated by Celecoxib (Compound)
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Lisinopril and Lisinopril (Compound) treats systemic scleroderma (Disease) and systemic scleroderma (Disease) is palliated by Celecoxib (Compound)
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Icosapent and Icosapent (Compound) downregulates RBM34 (Gene) and RBM34 (Gene) is downregulated by Celecoxib (Compound)